The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 02, 2018
Filed:
Nov. 11, 2016
Applicant:
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Shanghai, CN;
Inventors:
Qingping Zeng, Thousand Oaks, CA (US);
Warren S. Wade, San Diego, CA (US);
John Bruce Patterson, Ventura, CA (US);
Assignee:
Primary Examiner:
Int. Cl.
CPC ...
C07D 295/192 (2006.01); C07D 413/06 (2006.01); C07D 417/06 (2006.01); C07D 417/04 (2006.01); C07D 403/04 (2006.01); C07D 405/06 (2006.01); C07D 295/112 (2006.01); C07D 277/56 (2006.01); C07D 417/12 (2006.01); C07D 239/38 (2006.01); C07D 249/06 (2006.01); C07D 207/16 (2006.01); C07D 307/68 (2006.01); C07D 239/26 (2006.01); C07D 487/08 (2006.01); C07D 207/14 (2006.01); C07D 207/08 (2006.01); C07D 213/74 (2006.01); C07D 295/108 (2006.01); C07D 401/12 (2006.01); C07D 213/38 (2006.01); C07D 211/26 (2006.01); C07D 211/58 (2006.01); C07D 401/04 (2006.01); C07D 295/26 (2006.01); C07D 295/32 (2006.01); C07D 277/12 (2006.01); C07D 263/34 (2006.01); C07D 409/12 (2006.01); C07D 333/38 (2006.01); C07D 277/18 (2006.01);
U.S. Cl.
CPC ...
C07D 487/08 (2013.01); C07D 207/08 (2013.01); C07D 207/14 (2013.01); C07D 207/16 (2013.01); C07D 211/26 (2013.01); C07D 211/58 (2013.01); C07D 213/38 (2013.01); C07D 213/74 (2013.01); C07D 249/06 (2013.01); C07D 263/34 (2013.01); C07D 277/12 (2013.01); C07D 277/18 (2013.01); C07D 295/108 (2013.01); C07D 295/112 (2013.01); C07D 295/26 (2013.01); C07D 295/32 (2013.01); C07D 307/68 (2013.01); C07D 333/38 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 409/12 (2013.01);
Abstract
The invention provides compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.